FDA fast track designation facilitates expedited development of DPTX3186, recognizing its potential to address serious unmet ...
FOG-001 has been granted FDA fast track designation for desmoid tumors, expediting its development and review process. Preliminary trial data show FOG-001's significant antitumor activity, with an 80% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback